68Gallium- and 90Yttrium-/177Lutetium: “theranostic twins” for diagnosis and treatment of NETs

Rudolf A. Werner, Christina Bluemel, Martin S. Allen-Auerbach, Takahiro Higuchi, Ken Herrmann

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Abundant expression of somatostatin receptors (SSTR) is frequently identified in differentiated neuroendocrine tumors and may serve as potential target for diagnostic imaging and treatment. This article discusses the “theranostic approach” of SSTR-targeting compounds including an overview of its role for diagnosis, staging and restaging, discussing its way to being established in clinical routine, and giving an outlook about further potentially relevant developments.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalAnnals of nuclear medicine
Volume29
Issue number1
DOIs
Publication statusPublished - Jan 1 2015
Externally publishedYes

Fingerprint

Somatostatin Receptors
Neuroendocrine Tumors
Diagnostic Imaging
Therapeutics
Theranostic Nanomedicine

Keywords

  • Neuroendocrine tumor
  • PET/CT
  • PRRT
  • Radionuclide therapy
  • SPECT/CT
  • Theranostic

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

68Gallium- and 90Yttrium-/177Lutetium : “theranostic twins” for diagnosis and treatment of NETs. / Werner, Rudolf A.; Bluemel, Christina; Allen-Auerbach, Martin S.; Higuchi, Takahiro; Herrmann, Ken.

In: Annals of nuclear medicine, Vol. 29, No. 1, 01.01.2015, p. 1-7.

Research output: Contribution to journalArticle

Werner, Rudolf A. ; Bluemel, Christina ; Allen-Auerbach, Martin S. ; Higuchi, Takahiro ; Herrmann, Ken. / 68Gallium- and 90Yttrium-/177Lutetium : “theranostic twins” for diagnosis and treatment of NETs. In: Annals of nuclear medicine. 2015 ; Vol. 29, No. 1. pp. 1-7.
@article{8707cd1595bf4ce8b5a75378424c2a9f,
title = "68Gallium- and 90Yttrium-/177Lutetium: “theranostic twins” for diagnosis and treatment of NETs",
abstract = "Abundant expression of somatostatin receptors (SSTR) is frequently identified in differentiated neuroendocrine tumors and may serve as potential target for diagnostic imaging and treatment. This article discusses the “theranostic approach” of SSTR-targeting compounds including an overview of its role for diagnosis, staging and restaging, discussing its way to being established in clinical routine, and giving an outlook about further potentially relevant developments.",
keywords = "Neuroendocrine tumor, PET/CT, PRRT, Radionuclide therapy, SPECT/CT, Theranostic",
author = "Werner, {Rudolf A.} and Christina Bluemel and Allen-Auerbach, {Martin S.} and Takahiro Higuchi and Ken Herrmann",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/s12149-014-0898-6",
language = "English",
volume = "29",
pages = "1--7",
journal = "Annals of Nuclear Medicine",
issn = "0914-7187",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - 68Gallium- and 90Yttrium-/177Lutetium

T2 - “theranostic twins” for diagnosis and treatment of NETs

AU - Werner, Rudolf A.

AU - Bluemel, Christina

AU - Allen-Auerbach, Martin S.

AU - Higuchi, Takahiro

AU - Herrmann, Ken

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Abundant expression of somatostatin receptors (SSTR) is frequently identified in differentiated neuroendocrine tumors and may serve as potential target for diagnostic imaging and treatment. This article discusses the “theranostic approach” of SSTR-targeting compounds including an overview of its role for diagnosis, staging and restaging, discussing its way to being established in clinical routine, and giving an outlook about further potentially relevant developments.

AB - Abundant expression of somatostatin receptors (SSTR) is frequently identified in differentiated neuroendocrine tumors and may serve as potential target for diagnostic imaging and treatment. This article discusses the “theranostic approach” of SSTR-targeting compounds including an overview of its role for diagnosis, staging and restaging, discussing its way to being established in clinical routine, and giving an outlook about further potentially relevant developments.

KW - Neuroendocrine tumor

KW - PET/CT

KW - PRRT

KW - Radionuclide therapy

KW - SPECT/CT

KW - Theranostic

UR - http://www.scopus.com/inward/record.url?scp=84939894859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939894859&partnerID=8YFLogxK

U2 - 10.1007/s12149-014-0898-6

DO - 10.1007/s12149-014-0898-6

M3 - Article

C2 - 25139472

AN - SCOPUS:84939894859

VL - 29

SP - 1

EP - 7

JO - Annals of Nuclear Medicine

JF - Annals of Nuclear Medicine

SN - 0914-7187

IS - 1

ER -